Personalisation of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
Prospective, Randomized, Multicenter, Controlled Trial Assessing the Personalization of Mean Arterial Pressure in Adult Patients With Cardiogenic Shock
- Cardiogenic Shock
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- CMC Ambroise Paré
- Enrolment target
- 406
- Started
- 26 March 2026
- Main results due
- 25 July 2029
- Study sites
- 11
- Registry updated
- 29 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Aged ≥18 years * Cardiogenic shock state, according to the consensus definition, * SCAI (Society for Cardiovascular Angiography and Interventions) classification ≥ C * Consent from the patient or close relative / trusted person or emergency inclusion procedure * Benefiting fromciary of a social security scheme Exclusion Criteria: * Catecholamine infusion for more than 24 consecutive hours; * CVP \< 5 mm Hg at inclusion; * MAP \> 70 mmHg at inclusion; * Chronic kidney disease stage G4 (defined by an eGFR between 15-29 ml/min/1.73 m²) or G5 (defined by an eGFR less than 15 ml/min/1.73 m²) according to the KDIGO CKD classification at inclusion; * Chronic dialysis or presence of renal replacement therapy criteria at inclusion ; * Recovered cardiopulmonary arrest within 7 days prior to inclusion; * Patient already on mechanical circulatory support at inclusion before enrollment (patients who receive support after inclusion will not be excluded); * Primary diagnosis of tamponade, pulmonary embolism, or septic shock; * Hypersensitivity to norepinephrine tartrate or to any of the following excipients: sodium chloride, hydrochloric acid or sodium hydroxide water for injectable preparations; * Absence of central venous access; * Known pregnancy or current breastfeeding; * Under legal guardianship, curatorship, or judicial protection.
What this study is about
In the sponsor’s own words, from the registry.
Cardiogenic shock is a life-threatening condition characterized by inadequate cardiac output, leading to organ hypoperfusion and high mortality. Maintaining mean arterial pressure (MAP) is crucial, but standard targets may be insufficient due to venous congestion. Central venous pressure (CVP) can help assess effective perfusion pressure. This study investigates whether a personalized MAP target adjusted by CVP improves organ function and survival compared to standard MAP management.
Study sites(11)
CHU d'Amiens-Picardie
Amiens, France
Not yet recruiting
Hôpital Henri Mondor
Créteil, France
Recruiting
Hôpital Privé Jacques Cartier
Massy, France
Not yet recruiting
CMC Ambroise Paré - Hartmann
Neuilly-sur-Seine, France
Recruiting
CHU d'Orléans
Orléans, France
Not yet recruiting
Hôpital Lariboisière
Paris, France
Not yet recruiting
Hôpital Cochin
Paris, France
Not yet recruiting
Clinique NCT + /Saint-Gatien
Saint-Cyr-sur-Loire, France
Not yet recruiting
Centre Cardiologique du Nord
Saint-Denis, France
Not yet recruiting
CHRU de Strasbourg
Strasbourg, France
Not yet recruiting
CHU de Toulouse
Toulouse, France
Not yet recruiting
Showing 11 of 11 sites. 2 of the 11 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07345559. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me